𝔖 Bobbio Scriptorium
✦   LIBER   ✦

First-line Therapy for Chronic Myeloid Leukemia: New Horizons and an Update

✍ Scribed by Giuseppe Saglio; Michele Baccarani

Book ID
119936232
Publisher
Elsevier
Year
2010
Tongue
English
Weight
128 KB
Volume
10
Category
Article
ISSN
2152-2650

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

First-line therapy for chronic myeloid l
First-line therapy for chronic myeloid leukemia: Past, present, and future
✍ Carolina Pavlovsky; Hagop Kantarjian; Jorge E. Cortes πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 326 KB

## Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard‐dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, pr

Philadelphia-negative acute myeloid leuk
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia
✍ Carmen Fava; Jorge Cortes πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 306 KB πŸ‘ 2 views

## Induction of integrin b 1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma To the Editor: Acquired drug resistance continues to be one of the major obstacles hindering the successf